Read by QxMD icon Read

multiple mieloma

Irena Misiewicz-Krzeminska, Luis Antonio Corchete, Elizabeta A Rojas, Joaquín Martínez-López, Ramón García-Sanz, Albert Oriol, Joan Bladé, Juan José Lahuerta, Jesús San Miguel, María Victoria Mateos, Norma C Gutiérrez
Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low protein concentration obtained after CD138+ selection. A novel approach based on capillary nano-immunoassay could make it possible to automatically quantify dozens of proteins from each myeloma sample. Here, we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation...
March 15, 2018: Haematologica
Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, Lourdes Cordón, Maria-Teresa Cedena, Noemi Puig, Joaquin Martinez-Lopez, Laura Rosiñol, Norma C Gutierrez, María-Luisa Martín-Ramos, Albert Oriol, Ana-Isabel Teruel, María-Asunción Echeveste, Raquel de Paz, Felipe de Arriba, Miguel T Hernandez, Luis Palomera, Rafael Martinez, Alejandro Martin, Adrian Alegre, Javier De la Rubia, Alberto Orfao, María-Victoria Mateos, Joan Blade, Jesus F San-Miguel
Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively)...
September 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Tatiane Fernandes Farias, Karina da Silva Aguiar, Inajara Rotta, Klezia Morais da Silva Belletti, Juliane Carlotto
Objective: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. Methods: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters)...
July 2016: Einstein
S Expósito Vizcaíno, J Casanova-Mollà, L Escoda, S Galán, J Miró
INTRODUCTION: The neuropathic pain is the most habitual problem in the neuropathy induced by chemotherapy (NIQ) and the one that more interferes in the quality of life of the patients. His precocious detection turns out to be fundamental to reduce or to eliminate the problems that from this one stem. The aims of this study were: 1) determine the incident and NIQ's characteristics and neuropathic pain in patients with mieloma multiple (MM) treated with bortezomib, and 2) to evaluate the impact of the neuropathic pain in the activities of the daily life (AVD)...
July 27, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
Maria Teresa Petrucci, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, Rita Rizzi, Alessandro Gozzetti, Patrizia Falco, Carlo Lazzaro, Elisa Martelli, Mario Boccadoro, Francesco Lauria, Vincenzo Liso, Michele Cavo, Robert Foa
AIMS AND BACKGROUND: Multiple myeloma is the second most common hematological cancer. Although it accounts for only a relatively small percentage of all cancer types, the costs associated with managing multiple myeloma are considerable. Available studies are mainly focused on health care costs. The Costo del Mieloma Multiplo (Cost of MM, CoMiM) study investigated the cost of illness of multiple myeloma in Italy during one year of disease management. METHODS: CoMiM is a retrospective, prevalence-based, multi-center, cross-sectional study based on a stratified sample of patients seen during normal clinical practice (asymptomatic; symptomatic on drugs; symptomatic receiving autologous stem cell transplantation; plateau/remission)...
July 2013: Tumori
Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, Javier López-Jiménez, Javier de la Rubia, Miquel Granell, Joan Besalduch, Luis Palomera, Yolanda González, María Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T Hernández, Felipe de Arriba, Norma C Gutiérrez, María Luisa Martín-Ramos, María Teresa Cibeira, María Victoria Mateos, Joaquín Martínez, Adrián Alegre, Juan José Lahuerta, Jesús San Miguel, Joan Bladé
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years or younger with multiple myeloma. The primary endpoint was complete response (CR) rate postinduction and post-autologous stem cell transplantation (ASCT). Three hundred eighty-six patients were allocated to VTD (130), TD (127), or VBMCP/VBAD/B (129)...
August 23, 2012: Blood
B Paiva, N-C Gutiérrez, X Chen, M-B Vídriales, M-Á Montalbán, L Rosiñol, A Oriol, J Martínez-López, M-V Mateos, L López-Corral, E Díaz-Rodríguez, J-J Pérez, E Fernández-Redondo, F de Arriba, L Palomera, E Bengoechea, M-J Terol, R de Paz, A Martin, J Hernández, A Orfao, J-J Lahuerta, J Bladé, A Pandiella, J-F San Miguel
The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytometry in MM-PCs from 230 MM patients at diagnosis included in the Grupo Español de Mieloma (GEM)05>65 years trial as well as 56 high-risk smoldering MM (SMM). CD81 expression was detected in 45% (103/230) MM patients, and the detection of CD81(+) MM-PC was an independent prognostic factor for progression-free (hazard ratio=1...
August 2012: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
(no author information available yet)
No abstract text is available yet for this article.
2012: Medicina
Bruno Paiva, Norma C Gutiérrez, Laura Rosiñol, María-Belén Vídriales, María-Ángeles Montalbán, Joaquín Martínez-López, María-Victoria Mateos, María-Teresa Cibeira, Lourdes Cordón, Albert Oriol, María-José Terol, María-Asunción Echeveste, Raquel de Paz, Felipe de Arriba, Luis Palomera, Javier de la Rubia, Joaquín Díaz-Mediavilla, Anna Sureda, Ana Gorosquieta, Adrian Alegre, Alejandro Martin, Miguel T Hernández, Juan-José Lahuerta, Joan Bladé, Jesús F San Miguel
The achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; however, patients who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis. Thus, the identification of these patients is highly relevant. Here, we investigate which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n = 140) and GEM2005 < 65y (n = 101) trials...
January 19, 2012: Blood
Ramón García-Sanz, Adrián Alegre, Francisco Javier Capote, José Mariano Hernández, Laura Rosiñol, Javier de la Rubia, Anna Sureda, Felipe de Arriba, Joan Bargay, Joaquín Díaz Mediavilla, José García-Laraña, Juan José Lahuerta, María Victoria Mateos, Felipe Prósper, Jesús San Miguel, Joan Bladé
No abstract text is available yet for this article.
March 6, 2010: Medicina Clínica
Juan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, Laura Rosiñol, Anna Sureda, Javier de la Rubia, José García-Laraña, Rafael Martínez-Martínez, Miguel T Hernández-García, Dolores Carrera, Joan Besalduch, Felipe de Arriba, José María Ribera, Lourdes Escoda, Belén Hernández-Ruiz, Javier García-Frade, Concepción Rivas-González, Adrían Alegre, Joan Bladé, Jesús F San Miguel
PURPOSE: Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. PATIENTS AND METHODS: We analyzed 632 patients from the prospective Grupo Español de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation...
December 10, 2008: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Laura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, Javier de la Rubia, Felipe de Arriba, Juan José Lahuerta, José David González, Joaquín Díaz-Mediavilla, Belén Hernández, Javier García-Frade, Dolores Carrera, Angel León, Miguel Hernández, Pascual Fernández Abellán, Juan Miguel Bergua, Jesús San Miguel, Joan Bladé
One hundred ten patients with multiple myeloma (MM) failing to achieve at least near-complete remission (nCR) after a first autologous stem cell transplantation (ASCT) were scheduled to receive a second ASCT (85 patients) or a reduced-intensity-conditioning allograft (allo-RIC; 25 patients), depending on the human leukocyte antigen (HLA)-identical sibling donor availability. There was a higher increase in complete remission (CR) rate (40% vs 11%, P = .001) and a trend toward a longer progression-free survival (PFS; median, 31 months vs not reached, P = ...
November 1, 2008: Blood
M Perez-Andres, J Almeida, M Martin-Ayuso, M J Moro, M A Garcia-Marcos, I Moreno, M Dominguez, J Galende, N Heras, M I Gonzalez, J F San Miguel, A Orfao
The term "monoclonal gammopathy" (MG) includes a group of clonal plasma cell disorders, which show heterogeneous clinical behavior. While multiple myeloma (MM) and plasma cell leukemia (PCL) are incurable malignant diseases, most patients with MG of undetermined significance (MGUS) show an indolent/benign clinical course. Evidence has accumulated which supports the role of the bone marrow microenvironment in MG. Accordingly, the survival, drug-resistance and proliferation of MM cells have been shown to be largely dependent on a supportive microenvironment...
April 2004: Journal of Biological Regulators and Homeostatic Agents
R. Martinez-Conde, J. Aguirre, J. Lopez, J. Cacicedo
No abstract text is available yet for this article.
September 1996: Medicina Oral
T M Lotti, C Comacchi, I Ghersetich
Cutaneous necrotizing vasculitis (CNV) is a complex multisystem disease generally involving the skin and mucous membranes, often accompanied by renal, gastrointestinal, pericardial, neurological, and articular signs and symptoms. CNV may be idiopatical or occur in association with a drug, infection, or underlying disease. CNV has been shown in patients with chronic infections (viral, bacterial, protozoa, helminthic), serum sickness, a variety of collagen vascular diseases (systemic lupus erythematous, Sjögren's syndrome, rheumatoid arthritis, Behçet's disease) hyperglobulinemic states, cryoglobulinemia, bowel bypass syndrome, ulcerative colitis, cystic fibrosis, primary biliary cirrhosis and HIV infection...
1999: Advances in Experimental Medicine and Biology
E Marzetti, A Marzetti, O Palma, R W Pezzuto
Neoplastic proliferation of plasma cells results in a population of immunologically homogeneous cells that can produce diffuse (multiple myeloma) or localized (extramedullary plasmacytomas and solitary plasmacytoma of bone) disease. In otorhinolaryngologic literature these neoplasms are rarely described and their nosological arrangement is often confused. The presence of a plasma cell neoplasm can be a surprise and sometimes a diagnostic challenge to the head and neck surgeon. Proper management of such lesions needs to be individualized according to their expected biologic behaviour...
February 1996: Acta Otorhinolaryngologica Italica
F Pons Rocher, F Guallart Doménech, L Mompó Romero, J J Artazkozl del Toro, E Serrano Badía, J Dalmau Galofré, M Faubel Serra
We present a case of Amyloidosis of the oral cavity associated to multiple mieloma, with otolaryngological symptom. Review of structural characterization of the disease, its pathogenesis and clinical disorders when displayed in thyroid, oral cavity and upper respiratory tract.
1994: Anales Otorrinolaringológicos Ibero-americanos
G Monti, U G Cereda, E Pessina, N De Micheli, G C Grisetti, F Invernizzi
The results achieved with different approaches of chemotherapy protocols applied to 81 patients affected by multiple mieloma and followed up for a duration of 16 years in the geographical area pertaining to the Saronno County Hospital are presented. All the patients are divided into sub-groups, according to the type of treatment they required while being monitored over the years. Each single sub-group is evaluated according to the following criteria: objective response to therapy; median survival rates; toxic effects due to drug exposure...
February 11, 1983: Minerva Medica
U Coppetelli, G Avvisati, M Tribalto, M Cantonetti, G La Verde, T Petrucci, R Stasi, G Papa
Multiple myeloma still remains a fatal disease. However, in the last months new biological and clinical informations have been provided about this disease. In particular, the immunophenotype of myeloma cells seems indicate, in some patients, a clonal involvement of a stem cell in the pathogenesis of mieloma. Moreover, new biological insights concerning the cytokine network, have revealed a probable effect of some cytokines, such as IL6, IL3, IL4. Finally, new insights in the biology of multiple myeloma have been provided by studies of molecular biology and flow cytometry...
September 1992: Recenti Progressi in Medicina
O J Solis, R Gonzales, S De Luca, K A McKusick, M S Potsaid
Bone Scanning using 99m Tc-Diphosphonate is another diagnostic modality in the evaluation of multiple mieloma which allows the identification of bone lesions not demonstrable by conventional radiography. The use of 99m Tc-Diphosphonate is more convenient and less harmful than other radioactive isotopes utilized before.
April 1977: Revista Interamericana de Radiología
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"